Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

ETHOS Linear Accelerator at DKFZ in Heidelberg

ETHOS

ETHOS at DKFZ
© dkfz.de

ETHOS (Varian, Palo Alto, CA, USA) at DKFZ in Heidelberg is a state-of-the-art radiation therapy device used for the treatment of various forms of cancer. It offers a wide range of advanced features and technologies, including artificial intelligence, which enable precise and personalized radiation therapy. ETHOS is equipped with a high-resolution imaging system that not only allows for precise patient positioning, but also enables it to perform "online adaptive radiotherapy." This means that an optimized, customized radiation plan can be created for each radiation session, resulting in more precise and gentle treatment.

Overall, ETHOS in Heidelberg provides an innovative and patient-centered solution for radiation therapy, supporting precise, safe, and effective cancer treatment.

Modular Adaptive Radiotherapy System (MARS)

Shuttle-based transport, beginning at the 3T MRI scanner
© dkfz.de

Despite improvements in computed-tomography imaging, magnetic resonance imaging (MRI) still provides superior soft tissue contrast. This offers the possibility to precisely distinct tumor tissue from heathy tissue. Hence, the Division E050 at DKFZ in Heidelberg developed the Modular Adaptive Radiotherapy System (MARS), which combines the online adaptive radiotherapy device ETHOS with a high-field MRI device (VIDA, Siemens, Erlangen, Germany). Both devices are connected via a patient shuttle (Symphony, CQ Medical, UK). Using MR imaging and shuttle-based patient transport, we investigate the possibility to further optimize adaptive radiotherapy by performing offline MR-guidance. The figure on the right-hand side illustrates the shuttle-based transport, beginning at the 3T MRI scanner. Afterwards, the patients are shuttled to the neighboring ETHOS device.

Both the ETHOS and the VIDA MRI scanner are kindly funded by the Dieter Morszeck Foundation.

Publications

Kim JY, Tawk B, Knoll,M, Hoegen-Saßmannshausen P, Liermann J, Huber PE, Lifferth M, Lang C, Häring P, Gnirs R, Jäkel O, Schlemmer HP, Debus J, Hörner-Rieber J, Weykamp F. Clinical Workflow of Cone Beam Computer Tomography-Based Daily Online Adaptive Radiotherapy with Offline Magnetic Resonance Guidance: The Modular Adaptive Radiotherapy System (MARS). Cancers 16(6), 1210 (2024) [10.3390/cancers16061210]

Weykamp F, Meixner E, Arians N, Hoegen-Saßmannshausen P, Kim JY, Tawk B, Knoll M, Huber P, König L, Sander A, Mokry T, Meinzer C, Schlemmer HP, Jäkel O, Debus J, Hörner-Rieber J. Daily AI-Based Treatment Adaptation under Weekly Offline MR Guidance in Chemoradiotherapy for Cervical Cancer 1: The AIM-C1 Trial. J. Clin. Med. 2024, 13(4), 957 [https://doi.org/10.3390/jcm13040957]

to top
powered by webEdition CMS